Cresco Labs Inc. (OTCMKTS:CRLBF) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Cresco Labs Inc. (OTCMKTS:CRLBF) have earned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, two have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $2.50.

Several research firms have recently issued reports on CRLBF. Cormark lowered Cresco Labs from a “moderate buy” rating to a “hold” rating in a report on Monday, November 11th. Roth Capital raised Cresco Labs to a “strong-buy” rating in a research report on Sunday, November 10th. Finally, Atb Cap Markets cut Cresco Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th.

Cresco Labs Stock Up 4.4 %

Cresco Labs stock opened at $0.97 on Tuesday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. The stock has a market cap of $475.20 million, a PE ratio of -4.87 and a beta of 1.79. Cresco Labs has a fifty-two week low of $0.78 and a fifty-two week high of $2.65. The firm’s 50-day simple moving average is $1.12 and its 200 day simple moving average is $1.46.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.